Posted: August 17th, 2017

The patient receiving mitoxantrone (Novantrone) for treatment of secondary progressive multiple sclerosis (MS) is closely monitored for

The patient receiving mitoxantrone (Novantrone) for treatment of secondary progressive multiple sclerosis (MS) is closely monitored for
a) leukopenia and cardiac toxicity.
Mitoxantrone is an antineoplastic agent used primarily to treat leukemia and lyphoma but is also used to treat secondary progressive MS. Patients need to have laboratory tests ordered and the results closely monitored due to the potential for leukopenia and cardiac toxicity.
b) mood changes and fluid and electrolyte alterations.
Patients receiving corticosteroids are monitored for side effects related to corticosteroids such as mood changes and fluid and electrolyte alterations.
c) renal insufficiency.
Patients receiving mitoxantrone are closely monitored for leukopenia and cardiac toxicity.
d) hypoxia.
Patients receiving mitoxantrone are closely monitored for leukopenia and cardiac toxicity.